When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

被引：13

作者：

Adams, Jared R. ^{[1
]}

Angelotta, Cara

Bennett, Charles L.

机构：

[1] Dartmouth Coll, Hanover, NH USA

[2] Northwestern Univ, Chicago, IL 60611 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 19期

关键词：

D O I：

10.1200/JCO.2006.05.6812

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2975 / 2977

页数：3

共 21 条

[1]

Adams Jared R, 2002, Expert Opin Pharmacother, V3, P1273

[2] Using practice guidelines to assess cancer care quality [J].

Bach, PB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9041-9043

[3] Cost analyses of adjunct colony stimulating factors for acute leukemia: Can they improve clinical decision making [J].

Bennett, CL ;

Stinson, TJ ;

Laver, JH ;

Bishop, MR ;

Godwin, JE ;

Tallman, MS .

LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) :65-70

[4] Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines [J].

Bennett, CL ;

Weeks, JA ;

Somerfield, MR ;

Feinglass, J ;

Smith, TJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3676-3681

[5] ECONOMIC-ANALYSES OF CLINICAL-TRIALS IN CANCER - ARE THEY HELPFUL TO POLICY-MAKERS [J].

BENNETT, CL ;

ARMITAGE, JL ;

LESAGE, S ;

GULATI, SC ;

ARMITAGE, JO ;

GORIN, NC .

STEM CELLS, 1994, 12 (04) :424-429

[6] Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer - The 40% rule revisited [J].

Calhoun, EA ;

Schumock, GT ;

McKoy, JM ;

Pickard, S ;

Fitzner, KA ;

Heckinger, EA ;

Powell, EF ;

McCaffrey, KR ;

Bennett, CL .

PHARMACOECONOMICS, 2005, 23 (08) :767-775

[7] Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients [J].

Calhoun, EA ;

Chang, CH ;

Welshman, EE ;

Fishman, DA ;

Lurain, JR ;

Bennett, CL .

ONCOLOGIST, 2001, 6 (05) :441-445

[8] Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy [J].

Cosler, LE ;

Calhoun, EA ;

Agboola, C ;

Lyman, GH .

PHARMACOTHERAPY, 2004, 24 (04) :488-494

[9]

Drummond M, 2005, MED CARE, V43, P5

[10] Evaluation of conflict of interest in economic analyses of new drugs used in oncology [J].

Friedberg, M ;

Saffran, B ;

Stinson, TJ ;

Nelson, W ;

Bennett, CL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15) :1453-1457

← 1 2 3 →